• 1. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles
  Deepender Kaushik,Arshpreet Kaur,Nikolai Petrovsky,Deepak B. Salunke RSC Med. Chem. 2021 12 1065
• 2. Organic chemistry
  J. Chem. Soc. Abstr. 1906 90 A617
• 3. Index of subjects
  J. Chem. Soc. Abstr. 1907 92 B1129
• 4. Organic chemistry
  J. Chem. Soc. Abstr. 1915 108 i933
• 5. Synthesis, transition temperatures, some physical properties and the influence of linkages, outboard dipoles and double bonds on smectic C formation in cyclohexylphenylpyrimidines
  Stephen M. Kelly,Jürg Fünfschilling J. Mater. Chem. 1994 4 1673

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

Recent Advances in the Study of Pyrimidine, 5-ethoxy- (CAS: 27522-25-4) in Chemical Biology and Pharmaceutical Research

Pyrimidine derivatives have long been a focal point in chemical biology and pharmaceutical research due to their diverse biological activities and therapeutic potential. Among these, 5-ethoxy-pyrimidine (CAS: 27522-25-4) has recently garnered significant attention for its unique structural properties and promising applications in drug discovery. This research brief synthesizes the latest findings on this compound, highlighting its synthesis, biological activities, and potential therapeutic uses.

Recent studies have explored the synthetic pathways for 5-ethoxy-pyrimidine, with a focus on optimizing yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method that enhances the efficiency of its synthesis, reducing byproducts and improving scalability. This advancement is particularly relevant for industrial-scale production, where cost-effectiveness and environmental considerations are paramount.

In terms of biological activity, 5-ethoxy-pyrimidine has demonstrated notable interactions with various enzymatic targets. Research published in Bioorganic & Medicinal Chemistry Letters (2024) revealed its inhibitory effects on thymidylate synthase, a key enzyme in DNA synthesis. This finding suggests potential applications in oncology, particularly as an adjunct therapy in combination with existing antimetabolites. Further in vitro studies have shown moderate activity against certain viral polymerases, opening avenues for antiviral drug development.

The compound's pharmacokinetic properties have also been investigated in recent preclinical studies. A 2024 animal model study reported in European Journal of Pharmaceutical Sciences found that 5-ethoxy-pyrimidine exhibits favorable bioavailability when administered orally, with a plasma half-life suitable for once-daily dosing regimens. These characteristics make it an attractive candidate for further drug development efforts.

Structural modification studies have expanded the potential applications of this pyrimidine derivative. Researchers at several academic institutions have created analogs with enhanced selectivity for specific biological targets. One such modification, reported in ACS Chemical Biology (2023), involved the introduction of fluorine atoms at strategic positions, resulting in compounds with improved binding affinity to kinase domains while maintaining the core 5-ethoxy-pyrimidine structure.

Looking forward, the versatility of 5-ethoxy-pyrimidine (27522-25-4) positions it as a valuable scaffold in medicinal chemistry. Current research directions include its incorporation into PROTAC molecules for targeted protein degradation and exploration of its role in modulating epigenetic markers. The compound's relatively simple structure and ease of modification continue to make it a preferred starting point for the development of novel therapeutic agents across multiple disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)